Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer
Nicola Annels(University of Surrey), Hardev Pandha(University of Surrey)
Cited by 120
Related Papers
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
|Oncolytic Virotherapy|2016|75